Table 1.

Summary of outcome studies of statins in high-risk patients, dialysis, and kidney transplant recipients

Name of authorYearnInterventionsResults
Primary intervention
    Shepherd et al. (75)19956595Pravastatin (40 mg/d) versus placeboA 22% reduction in the risk of mortalitya
    Downs et al. (76)19986605Lovastatin (20 to 40 mg daily) versus placeboLovastatin reduces the risk for the first acute major coronary event.a
    Colhoun et al. (77)20042838Atorvastatin (10 mg daily) versus placeboAtorvastatin reduced the mortality rate by 27%.a
    Ridker et al. et al. (78)200817,802Rosuvastatin (20 mg/d) versus placeboRosuvastatin significantly reduced the incidence of major cardiovascular events in patients with high sensitivity C-reactive protein levelsa
Secondary and interventions
    4S Study (79)19944444Simvastatin on mortality and morbidity in patients with CADA 30% reduction in the risk of mortalitya
    LIPID Study (80)19989014Pravastatin (40 mg/d) versus placebo in patients with CADMortality: 6.4% in pravastatin group versus 8.3% in placebo groupa
    HPS study (55)200220,536Simvastatin (40 mg/d) versus placebo in patients with CAD or high risk24% reduction in cardiovascular eventsa
    CARE study (81)19964159Pravastatin (40 mg/d) versus placebo post-MI24% reduction in mortality ratea
    IDEAL study (82)2010999Atorvastatin (80 mg/d) versus simvastatin (20 to 40 mg/d)A primary endpoint occurred at 44.7% in the simvastatin group versus 37.9% in the atorvastatin groupa
    MIRACL study (83)20013086Atorvastatin (80 mg/d) versus placeboA primary endpoint occurred at 14.8% in the atorvastatin group versus 17.4% in the placebo group.a
    Pitt et al. (84)1999341Atorvastatin (80 mg/d) versus angioplastyIncidence of ischemic events was 36% lower in the atorvastatin group over an 18-month period.a
Dialysis population
    Wanner et al. (4D) (41)20041255Atorvastatin (20 mg/d) versus placeboAtorvastatin lowered the LDL level but had no significant effect on primary endpoint.
    Fellstrom et al. (AURORA) (42)20092776Rosuvastatin (10 mg/d) versus placeboRosuvastatin lowered the LDL level but had no significant effect on primary endpoint; CAD, coronary artery disease.
    SHARP (36)20109438Simvastatin/ezetimide (20/10 mg) versus placeboSimvastatin/ezetimide lowered the LDL level but had no significant effect on primary endpoint in dialysis patients.
Kidney transplantation Holdaas et al. (57)20051052Fluvastatin (40 mg/d) versus placeboFluvastatin (40 mg) lowered LDL, but no significant mortality benefitsa, reduced cardiovascular events
  • a Significantly better than control arm; CAD, coronary artery disease.